title: Molecular docking and panicolytic effect of 8-prenylnaringenin in the elevated T-maze.
abstract: The purpose of this study was to investigate the effects of the chronic administration of a racemic mixture of 8-prenylnaringenin (8-PN) on rats submitted to the elevated T-maze (ETM) model of generalized anxiety and panic disorders. The selective serotonin (SERT) reuptake inhibitor fluoxetine was used as a positive control. Rat locomotion was assessed in a circular arena following each drug treatment. The administration of racemic 8-PN for 21 d in rats increased one-way escape latencies from the ETM open arm, indicating a panicolytic effect. To evaluate the interactions of 8-PN with monoamine transporters, a docking study was performed for both the R and S configurations of 8-PN towards SERT, norepinephrine (NET) and dopamine transporters (DAT). The application of the docking protocol showed that (R)-8-PN provides greater affinity to all transporters than does the S enantiomer. This result suggests that enantiomer (R)-8-PN is the active form in the in vivo test of the racemic mixture.
authors.affiliation: Departamento de Química, Universidade Estadual de Maringá
authors.forename: Mariane Cristovão
authors.initials: MC
authors.lastname: Bagatin
authors.forename: Camila Santos Suniga
authors.initials: CS
authors.lastname: Tozatti
authors.forename: Layara Akemi
authors.initials: LA
authors.lastname: Abiko
authors.forename: Diego Alberto dos Santos
authors.initials: DA
authors.lastname: Yamazaki
authors.forename: Priscila Rebeca Alves
authors.initials: PR
authors.lastname: Silva
authors.forename: Leonardo Martins
authors.initials: LM
authors.lastname: Perego
authors.forename: Elisabeth Aparecida
authors.initials: EA
authors.lastname: Audi
authors.forename: Flavio Augusto Vicente
authors.initials: FA
authors.lastname: Seixas
authors.forename: Ernani Abicht
authors.initials: EA
authors.lastname: Basso
authors.forename: Gisele de Freitas
authors.initials: Gde F
authors.lastname: Gauze
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000378:metabolism* / Q000494:pharmacology*; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism; D044950:Flavanones / Q000494:pharmacology*; D005473:Fluoxetine / Q000494:pharmacology; D008297:Male; D008958:Models, Molecular; D009043:Motor Activity / Q000187:drug effects; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000378:metabolism; D016584:Panic Disorder / Q000188:drug therapy; D051381:Rats; D017208:Rats, Wistar; D050486:Serotonin Plasma Membrane Transport Proteins / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
chemical_list: D014151:Anti-Anxiety Agents; D050483:Dopamine Plasma Membrane Transport Proteins; D044950:Flavanones; D005473:Fluoxetine; D050484:Norepinephrine Plasma Membrane Transport Proteins; D050486:Serotonin Plasma Membrane Transport Proteins; D017367:Selective Serotonin Reuptake Inhibitors; C119737:8-prenylnaringenin